Compare BRTX & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRTX | ALZN |
|---|---|---|
| Founded | 1997 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Managed Health Care | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3M | 8.3M |
| IPO Year | N/A | 2021 |
| Metric | BRTX | ALZN |
|---|---|---|
| Price | $0.26 | $1.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | ★ 827.5K | 93.9K |
| Earning Date | 03-26-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $383,400.00 | N/A |
| Revenue This Year | $112.14 | N/A |
| Revenue Next Year | $139.81 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.70 | N/A |
| 52 Week Low | $0.22 | $1.58 |
| 52 Week High | $2.50 | $10.35 |
| Indicator | BRTX | ALZN |
|---|---|---|
| Relative Strength Index (RSI) | 11.42 | 33.99 |
| Support Level | $0.22 | $1.58 |
| Resistance Level | $1.13 | $2.11 |
| Average True Range (ATR) | 0.09 | 0.17 |
| MACD | -0.10 | -0.05 |
| Stochastic Oscillator | 3.22 | 19.91 |
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.